SpaceX vs. Quantinuum: Which Recent IPO Stock Is a Better Buy?

Quantinuum upsized its IPO to $60/share after strong demand, but shares have since fallen to about $47.06; Q1 revenue fell 73% to $5.2M and operating losses widened to $77.2M, though it still has $677M in cash. SpaceX’s stock rose 6% on lockup expiry after a Q2 earnings update, with revenue up 92% to $7.8B and operating loss shrinking to $143M, while capex surged to $18.4B (mostly $15.8B into AI) funded partly by a $25B bond issuance. Overall, the article frames SpaceX as the better long-term pick due to faster sales growth and improving losses despite rising capital needs.

Analysis

The cleanest market read is not “space and quantum are both hot,” but that capital is still rewarding businesses with some proof of monetization and punishing pure option value. That favors SPCX over QNT on a relative basis: one can justify a higher multiple when revenue is inflecting and losses are compressing, while the other is still priced for a far-distant adoption curve with no line of sight to operating leverage. In the next 1-3 months, the key mechanism is multiple compression risk for QNT if the market re-rates all frontier-tech IPOs from scarcity premium to execution premium.

Second-order, QNT is likely to pull in the entire quantum basket when the next data point disappoints, especially names with even less commercial proof like QUBT. IBM is a quieter beneficiary on the contrarian side: if quantum remains a long-duration race, incumbents with balance-sheet support and customer relationships may capture enterprise spend before pure plays reach scale. HON also keeps optionality with limited downside because the story is no longer about the legacy segment, but the equity market may not pay much for that until quantum revenues are independently durable.

The more important risk for SPCX is financing, not the latest quarter. Heavy AI capex and debt funding can work for a while, but if returns on invested capital lag, the stock becomes vulnerable to spread widening, covenant scrutiny, or a reset in growth assumptions over 6-18 months. For QNT, the falsifier is simple: any quarter where bookings or government awards fail to offset burn will likely extend the drawdown, while a large customer conversion would be the only near-term catalyst for a sharp squeeze.

Key Decisions for Investors

• Relative value: long SPCX / short QNT for 1-3 months to express ‘execution beats option value’; target a further 10-15% spread if the market keeps rewarding revenue visibility, stop if QNT announces a material commercial contract or SPCX growth decelerates meaningfully.
• Sell QNT strength into any IPO-style bounce; the setup is vulnerable to another multiple reset because the stock still trades on future adoption rather than current earnings power. Use a tight risk cap and cover if the company raises guidance on bookings or reports a step-change in backlog.
• Watch-list only: long IBM as a slower-moving hedge against quantum enthusiasm fading, since incumbents can monetize enterprise trust and services before pure plays prove scalability. Falsifier: if IBM’s quantum-related disclosures remain non-economic for multiple quarters, the optionality stays de minimis.
• Avoid chasing QUBT as a sympathy trade unless there is a disclosed contract or revenue inflection; it is likely to be the highest beta casualty if the sector de-rates. Best use is as a volatility short only if borrow/liquidity are workable.